Key terms

About ANGO

AngioDynamics, Inc. operates as a medical device company, which engages in the development, manufacturing and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It operates through the Med Tech and Med Device segments. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage, thrombolytic, and venous products. The company was founded by Howard S. Stern and Eamonn P. Hobbs on February 9, 1988 and is headquartered in Latham, NY.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest ANGO news

Apr 05 12:25pm ET Buy Rating Affirmed for AngioDynamics Amid Strong Sales and Strategic Growth Opportunities Apr 05 9:38am ET Krispy Kreme upgraded, Altice USA downgraded: Wall Street’s top analyst calls Apr 05 7:51am ET AngioDynamics upgraded to Outperform from Perform at Oppenheimer Apr 05 7:15am ET AngioDynamics upgraded to Outperform from Perform at Oppenheimer Apr 05 6:56am ET Buy Rating Reaffirmed for AngioDynamics Amidst Strategic Growth and Med-Tech Sector Potential Apr 04 7:42am ET AngioDynamics Unveils Financial Outlook and Growth Plans Apr 04 7:06am ET AngioDynamics reports Q3 adjusted EPS (16c), consensus (13c) Apr 04 7:05am ET Options Volatility and Implied Earnings Moves Today, April 04, 2024 Apr 04 6:50am ET AngioDynamics’ AlphaVac F18 system receives 510(k) clearance for PE Apr 01 5:21pm ET AngioDynamics settles litigation with Becton Dickinson Apr 01 7:00am ET Options Volatility and Implied Earnings Moves This Week, April 01 – April 05, 2024 Feb 22 7:46am ET AngioDynamics price target raised to $18 from $17 at Canaccord Feb 16 6:20am ET Analysts’ Top Healthcare Picks: AngioDynamics (ANGO), Corcept Therapeutics (CORT) Feb 16 6:13am ET AngioDynamics price target lowered to $14 from $18 at H.C. Wainwright Feb 15 4:14pm ET AngioDynamics sells PICC, Midline product portfolios for up to $45M in cash Feb 13 4:26pm ET AngioDynamics Announces Key Leadership and Board Changes Jan 23 8:10am ET FDA clears AngioDynamics Auryon XL Catheter to treat Peripheral Arterial Disease Jan 23 3:07am ET AngioDynamics’ Long-Time Director Meteny Retires Jan 08 7:55am ET Oppenheimer Keeps Their Hold Rating on AngioDynamics (ANGO) Jan 08 7:25am ET AngioDynamics price target lowered to $17 from $19 at Canaccord Jan 08 6:26am ET Buy Rating Maintained for AngioDynamics Amidst Strategic Restructuring and New Product Launches Jan 08 6:24am ET AngioDynamics price target lowered to $18 from $20 at H.C. Wainwright

No recent press releases are available for ANGO

ANGO Financials

1-year income & revenue

Key terms

ANGO Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

ANGO Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms